International Leprosy Association -
History of Leprosy

  • International Leprosy Association -
    History of Leprosy


    Dr Douglas S Walsh

    Status Medical Researcher
    Country USA


    Dr Douglas S Walsh is a Colonel in the Medical Corps of the US Army and Chief of the Department of Clinical Trials at the Walter Reed Army Institute of Research (WRAIR) in Maryland. His professional research interests encompass a wide range of tropical diseases and dermatoses, including leprosy and the Buruli ulcer.

    Between 1983 and 1985 Dr Walsh was a research assistant at Bethesda Research Laboratories, Rockville, Maryland and the Department of Molecular Virology, Gamble Institute of Medical Research, Cincinnati, Ohio. He received his MD from the George Washington University School of Medicine in 1989 and has thereafter served under the US Army, carrying out and directing medical research in Washington DC, Thailand, Georgia and Maryland. He is involved in teaching and holds various faculty posts in Dermatology. He is a member of numerous professional scientific societies.

    Dr Walsh has undertaken research on leprosy in the Philippines, and benefitted from hospital and clinical privileges at the Leonard Wood Memorial Center for Leprosy Research (American Leprosy Foundation), Cebu City, Philippines from 1996-01. He was appointed to the board of the Damien-Dutton Society for Leprosy Aid in 2002 and the Leonard Wood Memorial in 2006. In 2004 he was invited to present on “Alternative treatments for leprosy, including ROM” at the Leprosy Treatment Symposium, American Society of Tropical Medicine and Hygiene Meeting.

    This entry was added 5 September, 2006.

    Research Institute(s) associated with:
    Leonard Wood Memorial, Cebu, Philippines


    Dr Walsh has authored or co-authored over 90 articles (not including abstracts): those directly relevant to leprosy are listed below:

    • Walsh DS, Guido L, Fajardo TT. “The treatment of leprosy: a brief history and current chemotherapeutic recommendations”, Med Sci Res, 194 (1989): 271-3.
    • Villahermosa LG, Abalos RM, Walsh DS, Fajardo TT, Walsh GP. “Recombinant interleukin-2 in lepromatous leprosy lesions: immunologic and microbiologic consequences”, Clin Exp Dermatol, 22 (1997): 134-40.
    • Fajardo TT, Abalos RM, Dela Cruz EC, Villahermosa LG, Walsh DS, Cellona RV, Tan EV, Balagon MV, Walsh GP. “Clofazimine therapy for lepromatous leprosy: a historical perspective”, Int J Dermatol, 38 (1999): 70-4.
    • Villahermosa LG, Walsh DS, Fajardo TT, Abalos RM, dela Cruz EC, Veerasubramanian P, Walsh GP. “Resolution of lepromatous leprosy after short courses of amoxicillin/clavulanic acid and ofloxacin/clofazimine: a case report”, Intl J Dermatol, 38 (1999): 558-60 (Letter).
    • Hamerlinck FFV, Klatser PR, Walsh DS, Bos JD, Walsh GP, Faber WR. “Serum neopterin as a marker for reactional states in leprosy”, FEMS Immunol Med Microbiol, 24 (1999): 405-9.
    • Balagon MVF, Cellona RV, Fajardo TT, Villahermosa LG, Abalos RM, Tan EV, Walsh DS , Dela Cruz EC, Walsh GP. Detection of new leprosy cases at a walk-in skin clinic in Cebu City, Philippines highlights surveillance”, Int J Dermatol, 38 (1999): 796-7.
    • Walsh DS, Meyers WM, Krieg RE, Walsh GP. “Transmission of Mycobacterium ulcerans to the nine-banded armadillo”, Am J Trop Med Hyg, 61 (1999): 694-7.
    • Walsh DS , Villahermosa LG, Fajardo TT, Balagon MV, Cellona RV, Tan EV, Walsh GP. Cutaneous delayed-type hypersensitivity responsiveness in lepromatous and borderline lepromatous leprosy patients as determined by MULTITEST CMI. Southeast Asian J Trop Med Pub Health, 30 (1999): 518-26.
    • Walsh DS, Prieto-Go D, Abalos RM, Tuur-Saunders SM, Villahermosa LG, Jabien Z, Walsh GP, Fajardo TT. “Malignant T cell lymphoma mimicking lepromatous leprosy”, Clin Exp Derm, 26 (2001): 173-5.
    • Cellona RV, Balagon MVF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, Topolski R, Gelber RH, Walsh DS. “Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients”, Int J Lepr Other Mycobact Dis, 71 (2003): 308-319.
    • Villahermosa LG, Fajardo TT, Abalos RM, Cellona RV, Balagon MV, dela Cruz EC, Tan EV, Walsh GP, Walsh DS. “Parallel assessment of 24 monthly doses of rifampin, ofloxacin and minocycline (ROM) versus 2 year WHO multi-drug therapy (MDT) in multi-bacillary (MB) leprosy”, Am J Trop Med Hyg, 70 (2004): 197-200.
    • Walsh DS , Lane JE, Abalos RM, Myint KSA. “TUNEL and limited immunophenotypic analyses of apoptosis in paucibacillary and multibacillary leprosy lesions”, FEMS Imm Med Microbiol, 41 (2004): 265-9.
    • Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer J, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS. “A randomized, double-blind, double-dummy controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum”, Am J Trop Med Hyg, 72 (2005): 518-26.
    • Lane JE, Balagon MV, Dela Cruz EC, Abalos RM, Tan EV, Cellona RV, Sadaya PG, Walsh DS. “Mycobacterium leprae in untreated lepromatous leprosy – more than skin deep”, Clin Exp Derm, 31 (2006): 469-70.
    • Lane JE, Walsh DS, Meyers WM, Klassen-Fischer MK, Cohen DJ. “Borderline tuberculoid leprosy in a woman with armadillo exposure”, J Am Acad Derm (in press).

    In preparation:

    Book Chapter:

    Meyers WM, Walsh DS. “Leprosy and Buruli Ulcer: The Major Cutaneous Mycobacterioses”, Textbook of Pediatric Infectious Diseases (6 th edition, publication date 2007).

    Go back to previous page.